Related Experiment Video
Updated: Mar 27, 2026

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
IL6 Trans-signaling Promotes KRAS-Driven Lung Carcinogenesis.
Gavin D Brooks1, Louise McLeod1, Sultan Alhayyani1
1Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Monash University, Clayton, Victoria, Australia.
Interleukin-6 (IL6) trans-signaling drives KRAS-mutant lung adenocarcinoma. Blocking IL6 trans-signaling, a key pathway, suppressed tumor growth in mice and may offer a new therapeutic target for lung cancer.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Oncogenic KRAS mutations are common in lung adenocarcinoma.
- Interleukin-6 (IL6) signaling promotes KRAS-driven lung tumorigenesis, but the underlying mechanisms are unclear.
Purpose of the Study:
- To investigate the role of STAT3 activation, a key component of IL6 signaling, in KRAS-driven lung tumorigenesis.
- To explore IL6 trans-signaling as a potential therapeutic target.
Main Methods:
- Utilized a gp130(F/F):Kras(G12D) knock-in mouse model with hyperactivated STAT3.
- Assessed lung cancer progression, cytokine levels (IL6), and STAT3 activity.
- Investigated IL6 trans-signaling using anti-IL6 receptor antibodies and sgp130Fc inhibitor.
- Analyzed human lung adenocarcinoma specimens and patient serum for IL6 and soluble IL6 receptor (sIL6R) expression.
Main Results:
- The gp130(F/F):Kras(G12D) model exhibited accelerated lung adenocarcinoma development compared to controls.
- Genetic ablation of IL6 or STAT3, or blocking IL6 trans-signaling, significantly suppressed lung cancer.
- Elevated IL6 and sIL6R were observed in both the mouse model and human lung adenocarcinoma samples.
Conclusions:
- Hyperactivated IL6 trans-signaling via STAT3 is a critical driver of KRAS-driven lung adenocarcinoma.
- Targeting IL6 trans-signaling presents a promising therapeutic strategy for KRAS-mutant lung cancer.
- Clinical evaluation of IL6 trans-signaling inhibitors is warranted for lung adenocarcinoma treatment.
More Related Videos
Related Concept Videos
The Ras Gene
Ras is a...
MAPK Signaling Cascades
PI3K/mTOR/AKT Signaling Pathway
The JAK-STAT Signaling Pathway
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

